PROFILE
HATTORI Nobutaka, M.D., Ph.D.
Department of Drug Development for Parkinson's Disease
Short Biography
- 1985-1986
- M.D. Juntendo University Faculty of Medicine
Intern, Juntendo University Hospital
- 1986-1988
- Resident in Neurology, Department of Neurology, Fuji, National Hospital
- 1988-1989
- Assistant Professor of Neurology, Juntendo University
- 1990-1994
- Ph.D. Juntendo University Graduate School of Medicine
- 1990-1993
- Study Molecular Biology as a Special Graduate Student at Department of Biological Chemistry at the Faculty of Medicine, University of Nagoya
- 1994-1995
- Medical Staff, Department of Neurology, Tokyo Metropolitan Ebara Hospital
- 1995-1998
- Assistant Professor, Department of Neurology, Juntendo University
- 1999-2003
- Lecturer, Department of Neurology, Juntendo University
- 2003-2006
- Associate Professor, Department of Neurology, Juntendo University
- 2006-Present
- Professor and Chairman, Department of Neurology, Juntendo University Faculty of Medicine
- 2019-Present
- Dean, Juntendo University Faculty of Medicine
Keywords
- Parkinson's Disease
- Levodopa
- Alpha Synuclein
- Lipid Metabolism
- Antibody therapy
Main Research Topics and Interests
- Parkinson's disease
- Autophagy lysosome pathway
- Prion-like Propagation
- Levodopa therapy
Publications (in English)
- Original and Review Articles (792)
- Books (16)
- Total Impact Factor (3,830.664)
- Citation Index (31,512)
- h-index (77)
Recent Main Publications
- Hattori N. Movement disorders: advances in 2015. Lancet Neurol. 2016 Jan;15(1):8-9. doi: 10.1016/S1474-4422(15)00362-2. Review.
- Hatano T, Saiki S, Okuzumi A, Mohney RP, Hattori N. Identification of novel biomarkers for Parkinson's disease by metabolomic technologies. Journal of Neurology, Neurosurgery, and Psychiatry, 2016, 87:295-301
- Funayama M, Ohe K, Amo T, Furuya N, Yamaguchi J, Saiki S, Li Y, Ogaki K, Ando M, Yoshino H, Tomiyama H, Nishioka K, Hasegawa K, Saiki H, Satake W, Mogushi K, Sasaki R, Kokubo Y, Kuzuhara S, Toda T, Mizuno Y, Uchiyama Y, Ohno K, Hattori N: CHCHD2 mutations in autosomal dominant late-onset Parkinson's disease: a genome-wide linkage and sequencing study. Lancet Neurol, 2015 Mar; 14 (3): 274-82.
- Shiba-Fukushima K, Inoshita T, Hattori N, Imai Y: PINK1-mediated phosphorylation of Parkin boosts Parkin activity in Drosophila. PLoS Genet, 2014; 10: e1004391.
- Hattori N, Mochizuki H, Hasegawa K, Nomoto M, Uchida E, Terahara T, Okawa K, Fukuta H. Ropinirole Patch Versus Placebo, Ropinirole Extended-Release Tablet in Advanced Parkinson's Disease. Mov Disord. 2020 May 12. doi: 10.1002/mds.28071. Epub ahead of print.
- More
Other Specific Comments
- The aims of this department is to develop the disease modifying therapy and extended-release carbidopa–levodopa therapy for Parkinson’s disease.
- The Commendation for Science and Technology by the Minister of Education, Culture, Sports, Science and Technology, Research Category, May 30, 2014
Link
